# Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

> **NCT02101918** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Multiple Endocrine Neoplasia Type 1
- Pancreatic Neuroendocrine Carcinoma

## Interventions

- **RADIATION:** Computed Tomography Perfusion Imaging
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Ziv-Aflibercept

## Key facts

- **NCT ID:** NCT02101918
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-18
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101918, "Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02101918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*